NICE final guidance recommends anti-TNFs Humira and Remicade for Crohn's disease
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence, in the UK is recommending Abbott's Humira (adalimumab) and Schering-Plough's Remicade (infliximab, licensed from Johnson & Johnson) for the treatment of some Crohn's disease patients.
You may also be interested in...
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.